• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: BRIC nations emerging as leaders in global trial landscape

Report: BRIC nations emerging as leaders in global trial landscape

May 28, 2014
CenterWatch Staff

BRIC nations, including Brazil, Russia, India and China, are emerging leaders in the global clinical trials landscape, according to the Thomson Reuters report, Overcoming Clinical Challenges in BRIC Markets, which explores the benefits and challenges of conducting clinical trials in the pharmaceutical markets of the BRIC nations.

The study found while increased regulations, evolving clinical standards and complex pipelines have driven some sponsors out of the BRIC nations, a rise in rank for each country is expected over the next four years, indicating blossoming healthcare budgets and markets ripe with opportunities for development.

"Each BRIC nation faces its own challenges as an attractive market for clinical trials, but each also has its own unique landscape and reward," said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences.

In Brazil, the rapidly changing clinical landscape and complexity and lengthiness of approval and import processes have been cited as the biggest drawbacks. The multiple reviews required for placebo trials and the associated timelines and cost also have discouraged global sponsors.

Meanwhile, Russia and India face similar challenges. Regulations in both countries are being enacted faster than foreign pharma companies can keep up with. The upheaval of the healthcare system and tumultuous landscape in Russia are additional barriers.

China is the only BRIC country that has experienced an increase in the number of clinical trials initiated each year. Nevertheless, foreign sponsors continue to face challenges that limit their cost savings in the drug development process.

Despite these issues, the benefits of performing clinical trials in BRIC countries are numerous. A pool of almost three billion patients in research-rich centers across major cities leads to fast recruitment and cost-effective trials. Additionally, increased spending on healthcare and R&D has fostered a growing number of educated and trained health professionals as well as investigational-medicine product manufacturers and central laboratories.

"Industry leaders need to be fully informed of market trends and insights when making strategic decisions," Brett-Harris said.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing